A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes

(2016) Amer M. Zeidan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management

(2015) Guillermo Garcia-Manero   AMERICAN JOURNAL OF HEMATOLOGY

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Panobinostat for the Treatment of Multiple Myeloma

(2015) J. P. Laubach et al.   CLINICAL CANCER RESEARCH

Higher Infection Rate After 7- Compared With 5-Day Cycle of Azacitidine in Patients With Higher-Risk Myelodysplastic Syndrome

(2015) Yishai Ofran et al.   Clinical Lymphoma Myeloma & Leukemia

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

(2015) Paul G Richardson et al.   Expert Review of Anticancer Therapy

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

(2015)   Oncotarget

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

(2014) Lisa Pleyer et al.   ANNALS OF HEMATOLOGY

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

(2014) Mark Kirschbaum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

(2014) Jean-Pierre Issa et al.   CANCER

Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges

(2014) Michael Lübbert et al.   CANCER

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

(2014) P Tan et al.   Blood Cancer Journal

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

(2013) Yun-Gyoo Lee et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

(2013) D J DeAngelo et al.   LEUKEMIA

Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic Syndromes

(2013) Hina Khan et al.   SEMINARS IN HEMATOLOGY

Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

(2012) Drorit Merkel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Azacitidine for the treatment of patients with acute myeloid leukemia

(2011) Luca Maurillo et al.   CANCER

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

(2010) Warren Fiskus et al.   CANCER BIOLOGY & THERAPY

Epigenetic Changes in the Myelodysplastic Syndrome

(2010) Jean-Pierre Issa   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Myelodysplastic syndromes

(2008) S. D. Nimer   BLOOD